利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.046 秒)

    Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
    1.
    发明授权
    Method of treating ciliary dyskinesia with uridine triphosphates and related compounds 失效
    用尿苷三磷酸和相关化合物治疗睫状肌运动障碍的方法

    公开(公告)号：US06420347B1

    公开(公告)日：2002-07-16

    申请号：US09101840

    申请日：1998-07-17

    申请人： Karla M. Jacobus ,  Benjamin R. Yerxa ,  William Pendergast ,  Richard C. Boucher, Jr. ,  Janet L. Rideout ,  David J. Drutz ,  Michael K. James ,  Monroe Jackson Stutts ,  Cary Geary ,  Edwardo R. Lazarowski

    发明人： Karla M. Jacobus ,  Benjamin R. Yerxa ,  William Pendergast ,  Richard C. Boucher, Jr. ,  Janet L. Rideout ,  David J. Drutz ,  Michael K. James ,  Monroe Jackson Stutts ,  Cary Geary ,  Edwardo R. Lazarowski

    IPC分类号： A61K3170

    CPC分类号： A61K31/70

    摘要： A method of stimulating ciliary beat frequency in a subject in need of such treatment is disclosed. The method comprises administering to the airways, ears, eyes, or genito-urinary tract of the subject a triphosphate nucleotide such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to stimulate ciliary beat frequency. This method is useful for treating patients afflicted with ciliary dyskinesia, Kartagener's syndrome, or any other disease involving dysfunction of ciliary movement, such as male infertility caused by impairment of propulsion of the spermatozoa or immune deficiency caused by impairment of ciliary movement in neutrophils or macrophages. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal spray or nasal or eye drops), oral, inhaled by nebulization, topical, injected, suppository, intra-operative by instillation or application, or ex vivo direct application to spermatozoa.

    摘要翻译： 公开了一种在需要这种治疗的受试者中刺激睫状肌搏动频率的方法。 该方法包括向受试者的气道，耳朵，眼睛或生殖泌尿道施用有效刺激的量的三磷酸核苷酸，例如尿苷5'-三磷酸（UTP），UTP类似物或任何其它类似物 睫毛拍频。 该方法可用于治疗患有睫状肌运动障碍，Kartagener综合征或涉及睫状肌运动功能障碍的任何其他疾病，例如由嗜中性粒细胞或巨噬细胞的睫状肌运动损伤引起的精子推进或免疫缺陷引起的男性不育症 。 还公开了药物制剂及其制备方法。 给药方法包括任何液体悬浮液（包括鼻喷雾或鼻腔或滴眼液），口服，通过雾化吸入，局部注射，注射，栓剂，通过滴注或施用手术，或离体直接施用于精子。

    Method of promoting cervical and vaginal secretions
    3.
    发明授权
    Method of promoting cervical and vaginal secretions 有权
    促进子宫颈和阴道分泌物的方法

    公开(公告)号：US07432252B1

    公开(公告)日：2008-10-07

    申请号：US09531851

    申请日：2000-03-20

    申请人： William Pendergast ,  Sammy Ray Shaver ,  David J. Drutz ,  Janet L. Rideout ,  Benjamin R. Yerxa

    发明人： William Pendergast ,  Sammy Ray Shaver ,  David J. Drutz ,  Janet L. Rideout ,  Benjamin R. Yerxa

    IPC分类号： A61K31/70

    CPC分类号： C07H21/00

    摘要： The present invention provides a method of stimulating cervical and vaginal secretions in a mammal by treatment with P2Y2 and/or P2Y4 purinergic receptor agonists. Treatment of vaginal dryness associated with menopause, chemotherapy, and various disease states as well as the treatment of vulvar pain is discussed. Suitable agonists such as UTP, CTP, ATP, dinucleotides and analogs thereof are disclosed.

    摘要翻译： 本发明提供了通过用P2Y2和/或P2Y4N4嘌呤能受体激动剂治疗来刺激哺乳动物的宫颈和阴道分泌物的方法。 讨论了与绝经，化疗和各种疾病状态相关的阴道干燥的治疗以及外阴疼痛的治疗。 公开了合适的激动剂，例如UTP，CTP，ATP，二核苷酸及其类似物。

    Pharmaceutical compositions of uridine triphosphate
    5.
    发明授权
    Pharmaceutical compositions of uridine triphosphate 失效
    尿苷三磷酸的药物组合物

    公开(公告)号：US5968913A

    公开(公告)日：1999-10-19

    申请号：US996740

    申请日：1997-12-23

    申请人： Karol K. LaCroix ,  Christy L. Shaffer ,  Karla M. Jacobus ,  Janet L. Rideout ,  David J. Drutz ,  Richard C. Evans ,  William Pendergast

    发明人： Karol K. LaCroix ,  Christy L. Shaffer ,  Karla M. Jacobus ,  Janet L. Rideout ,  David J. Drutz ,  Richard C. Evans ,  William Pendergast

    IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7072 ,  A61K47/02 ,  A61P43/00

    CPC分类号： A61K9/0078 ,  A61K31/7072 ,  A61K47/02 ,  A61K9/08

    摘要： Novel pharmaceutical compositions of uridine 5'-triphosphate (UTP) for use in promoting increased mucociliary clearance of retained mucous secretions of the human airways, middle/inner ears or sinuses are disclosed. Novel Formulation I comprises UTP and aqueous solution having a therapeutic concentration between 5 and 45 mg/mL, a controlled tonicity within the range of 250 to 100 mOsM, a pH between 7.0 and 7.5, and is sterile. The pH-adjusted composition is capable of long-term storage in the refrigerated state with a shelf life of up to 30 months. Formulation I may be delivered therapeutically either in a nebulized form or in a liquid form. Novel Formulation II comprises UTP in an aqueous solution or suspension having a therapeutic concentration approaching the limit of UTP's solubility at ambient temperature. This high concentration allows delivery of a therapeutic amount of UTP in very small volumes (50 to 100 .mu.L) suitable for administration via portable hand-held devices such as metered dose inhalers. Formulation II has extended shelf life without the need for refrigeration after being dispensed to the patient.

    摘要翻译： 公开了用于促进对人气道，中耳/内耳或窦的保留的粘液分泌物的增加的粘膜纤毛清除的尿苷5'-三磷酸（UTP）的新型药物组合物。 新型制剂I包括治疗浓度为5至45mg / mL的UTP和水溶液，在250至100mOsM范围内的控制张力度，7.0至7.5之间的pH，并且是无菌的。 经pH调节的组合物能够在冷藏状态下长期储存，保质期长达30个月。 制剂I可以以雾化形式或液体形式治疗性递送。 新型制剂II包含在具有接近UTP在环境温度下的溶解度的极限的治疗浓度的水溶液或悬浮液中的UTP。 这种高浓度允许以非常小的体积（50至100μL）递送治疗量的UTP，其适用于经由便携式手持式装置例如计量吸入器的给药。 制剂II具有延长的保存期限，而不需要在分配给患者后进行制冷。

    Method of treating otitis media with uridine triphosphates and related compounds
    7.
    发明授权
    Method of treating otitis media with uridine triphosphates and related compounds 失效
    用尿苷三磷酸和相关化合物治疗中耳炎的方法

    公开(公告)号：US06423694B1

    公开(公告)日：2002-07-23

    申请号：US08604463

    申请日：1996-02-21

    申请人： David J. Drutz ,  Janet L. Rideout ,  Karla M. Jacobus

    发明人： David J. Drutz ,  Janet L. Rideout ,  Karla M. Jacobus

    IPC分类号： A61K3170

    CPC分类号： A61K31/7076 ,  A61K31/7072

    摘要： A method of promoting drainage of congested middle ear fluid in a subject in need of such treatment is disclosed. The method comprises administering to the middle ear of the subject a uridine triphosphate such as uridine 5′-triphosphate (UTP), an analog of UTP, or any other analog, in an amount effective to promote drainage of congested middle ear fluid by hydrating mucous secretions in the middle ear or by stimulating ciliary beat frequency in the middle ear or eustachian tube. The method is useful for treating patients afflicted with otitis media and other middle ear diseases, otitis externa, and inner ear diseases including Ménière's Disease. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or spray), oral, inhaled by nebulization, topical, injected or suppository form.

    摘要翻译： 公开了一种在需要这种治疗的受试者中促进拥挤的中耳液的引流的方法。 该方法包括向受试者的中耳施用尿苷三磷酸，例如尿苷5'-三磷酸（UTP），UTP的类似物或任何其它类似物，其量可有效地促进通过保湿粘液促进拥挤的中耳液的引流 中耳分泌物或通过刺激中耳或咽鼓管中的睫状肌搏动频率。 该方法可用于治疗患有中耳炎和其他中耳疾病，外耳炎和内耳疾病（包括梅尼埃病）的患者。 还公开了药物制剂及其制备方法。 给药方法包括任何液体悬浮液（包括滴鼻剂或喷雾剂），口服，通过雾化，局部，注射或栓剂形式吸入。

    Methods and compositions for detection of Legionnaires' disease
    8.
    发明授权
    Methods and compositions for detection of Legionnaires' disease 失效
    检测军团病的方法和组成

    公开(公告)号：US4722891A

    公开(公告)日：1988-02-02

    申请号：US622567

    申请日：1984-06-20

    申请人： David J. Drutz ,  Barry I. Eisenstein ,  N. Cary Engleberg

    发明人： David J. Drutz ,  Barry I. Eisenstein ,  N. Cary Engleberg

    IPC分类号： A61K39/00 ,  C07K14/195 ,  C12N1/20 ,  C12N15/09 ,  C12Q1/04 ,  C12R1/01 ,  C12R1/19 ,  G01N33/569 ,  G01N33/577 ,  C12N15/00 ,  G01N33/531 ,  G01N33/554

    CPC分类号： G01N33/56911 ,  C07K14/195 ,  Y10S530/806 ,  Y10S530/808 ,  Y10S530/81 ,  Y10S530/825

    摘要： Recombinant E. coli clones which cell surface-express Legionella pneumophila antigens, a method for utilizing these clones for the detection of Legionella antibodies in a clinical sample, and a method for isolation of mono-specific anti-Legionella antibodies are disclosed. The recombinant clones are produced by ligating fragmented Legionella DNA to pBR322 which is then used to transform the appropriate E. coli host. Clones that cell surface-express individual Legionella antigens are selected by screening cellularly intact clones using anti-Legionella antibodies to probe for cell surface expression. An enzyme-linked immunosorbant assay (ELISA) is disclosed which utilizes the Legionella antigen-expressing clones to detect anti-Legionella antibodies.

    摘要翻译： 公开了细胞表面表达嗜肺军团菌抗原的重组大肠杆菌克隆，临床样品中利用这些克隆用于检测军团菌抗体的方法和分离单特异性抗军团菌抗体的方法。 通过将碎片的Legionella DNA与pBR322连接产生重组克隆，然后将其用于转化合适的大肠杆菌宿主。 通过使用抗军团菌抗体筛选细胞完整的克隆来探测细胞表面表达来选择细胞表面表达个体军团菌抗原的克隆。 公开了一种酶联免疫吸附测定（ELISA），其利用表达军团菌抗原的克隆来检测抗军团菌抗体。